Bronchoalveolar lavage fluid cfDNA liquid biopsy-guided neoadjuvant lazertinib in resectable EGFR-mutant non-small cell lung cancer: a prospective phase II study.
4 affiliations
- 1Precision Medicine Lung Cancer Center, Konkuk University Medical Center, Seoul, Republic of Korea.
- 2Department of Pathology, Konkuk University School of Medicine, Seoul, Republic of Korea.
- 3Department of Thoracic Surgery, Konkuk University School of Medicine, Seoul, Republic of Korea.
- 4Precision Medicine Lung Cancer Center, Dankook University Medical Center, Cheonan, Republic of Korea.
Abstract
Reliable preoperative molecular testing is increasingly important in resectable non-small cell lung cancer (NSCLC), particularly when tissue biopsy is not feasible or yields insufficient material. We evaluated the feasibility of bronchoalveolar lavage fluid cell-free DNA liquid biopsy (BALiquid) as a preoperative epidermal growth factor receptor (EGFR) genotyping platform and assessed the clinical efficacy of neoadjuvant lazertinib in patients with potentially resectable EGFR-mutant NSCLC. A total of 128 patients with computed tomography (CT) findings suggestive of potentially resectable lung cancer underwent bronchoscopy with bronchoalveolar lavage near the target lesion. EGFR genotyping was performed using polymerase chain reaction (PCR)-based BALF cfDNA analysis. Patients with sensitizing EGFR mutations detected by BALiquid received neoadjuvant lazertinib for 9 weeks followed by surgical resection. Diagnostic performance, radiologic response, surgical outcomes, pathologic response, and safety were evaluated. Among 48 patients with BALiquid-detected EGFR mutations, 40 were enrolled and 34 completed neoadjuvant lazertinib followed by surgery. BALiquid EGFR genotyping demonstrated a sensitivity of 74%, a specificity of 97.0%, a positive predictive value of 97.4%, a negative predictive value of 71.7% and 83.3% of concordance rate compared with surgical tissue genotyping. The all-treated objective response rate (ORR) was 57.5% [23/40; 95% confidence interval (CI): 40.9-73.0%], and the ORR in the per-protocol population was 67.6% (23/34; 95% CI: 49.5-82.6%). R0 resection was achieved in 33 of 34 patients. Pathologic downstaging occurred in 55.9% of patients, and major pathologic response was achieved in 6 of 34 patients (17.6%). Grade 3 or higher treatment-related adverse events occurred in 4/40 patients (10.0%). BALiquid may serve as a complemental preoperative EGFR genotyping approach to provide genetic information when tissue is unavailable or insufficient. BALiquid-guided neoadjuvant lazertinib demonstrated meaningful antitumor activity, favorable surgical outcomes, and an acceptable safety profile in patients with potentially resectable EGFR-mutant NSCLC.
Related
- Molecular detection of Acanthamoeba genotypes and Pneumocystis jirovecii in bronchoalveolar lavage specimens from immunocompetent patients with respiratory disorders
- Metagenomic next-generation sequencing of bronchoalveolar lavage fluid unravels brucellosis in a patient with chronic lung disease and venous thrombosis: A case report.
- Viral metagenomic characterization of HAdV-B-related signals in bronchoalveolar lavage fluid from pediatric and adult clinical cohorts
- Bronchoalveolar Lavage Metagenomic Sequencing in the Early Post-Lung Transplantation Period: A Pilot Comparison with Microbiologic Culture
- Inflammatory and immunologic analysis of bronchoalveolar lavage from patients with post-COVID-19 lung disease
BibTeX
@article{kim2026bronchoalveolar,
title = {{Bronchoalveolar lavage fluid cfDNA liquid biopsy-guided neoadjuvant lazertinib in resectable EGFR-mutant non-small cell lung cancer: a prospective phase II study.}},
author = {In Ae Kim and Heejoung Kim and Jae Young Hur and Wan Seop Kim and Young Whan Kim and Song Am Lee and Jae Joon Hwang and Kye Young Lee},
journal = {Translational lung cancer research},
year = {2026},
month = sep,
doi = {10.21037/tlcr-2026-0915},
url = {https://europepmc.org/article/MED/42999407},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Bronchoalveolar lavage fluid cfDNA liquid biopsy-guided neoadjuvant lazertinib in resectable EGFR-mutant non-small cell lung cancer: a prospective phase II study.
AU - In Ae Kim
AU - Heejoung Kim
AU - Jae Young Hur
AU - Wan Seop Kim
AU - Young Whan Kim
AU - Song Am Lee
AU - Jae Joon Hwang
AU - Kye Young Lee
PY - 2026
DA - 2026/09/28
JO - Translational lung cancer research
DO - 10.21037/tlcr-2026-0915
UR - https://europepmc.org/article/MED/42999407
AB - Reliable preoperative molecular testing is increasingly important in resectable non-small cell lung cancer (NSCLC), particularly when tissue biopsy is not feasible or yields insufficient material. We evaluated the feasibility of bronchoalveolar lavage fluid cell-free DNA liquid biopsy (BALiquid) as a preoperative epidermal growth factor receptor (EGFR) genotyping platform and assessed the clinical efficacy of neoadjuvant lazertinib in patients with potentially resectable EGFR-mutant NSCLC. A total of 128 patients with computed tomography (CT) findings suggestive of potentially resectable lung cancer underwent bronchoscopy with bronchoalveolar lavage near the target lesion. EGFR genotyping was performed using polymerase chain reaction (PCR)-based BALF cfDNA analysis. Patients with sensitizing EGFR mutations detected by BALiquid received neoadjuvant lazertinib for 9 weeks followed by surgical resection. Diagnostic performance, radiologic response, surgical outcomes, pathologic response, and safety were evaluated. Among 48 patients with BALiquid-detected EGFR mutations, 40 were enrolled and 34 completed neoadjuvant lazertinib followed by surgery. BALiquid EGFR genotyping demonstrated a sensitivity of 74%, a specificity of 97.0%, a positive predictive value of 97.4%, a negative predictive value of 71.7% and 83.3% of concordance rate compared with surgical tissue genotyping. The all-treated objective response rate (ORR) was 57.5% [23/40; 95% confidence interval (CI): 40.9-73.0%], and the ORR in the per-protocol population was 67.6% (23/34; 95% CI: 49.5-82.6%). R0 resection was achieved in 33 of 34 patients. Pathologic downstaging occurred in 55.9% of patients, and major pathologic response was achieved in 6 of 34 patients (17.6%). Grade 3 or higher treatment-related adverse events occurred in 4/40 patients (10.0%). BALiquid may serve as a complemental preoperative EGFR genotyping approach to provide genetic information when tissue is unavailable or insufficient. BALiquid-guided neoadjuvant lazertinib demonstrated meaningful antitumor activity, favorable surgical outcomes, and an acceptable safety profile in patients with potentially resectable EGFR-mutant NSCLC.
SN - 2218-6751
SN - 2226-4477
ER -